A new experimental drug is showing promise in targeting an incurable form of blood cancer.
The experimental drug, CBPD-409, was found to kill myeloma cells at very low doses while having limited effects on healthy cells.
It works by removing two proteins, CBP and p300, which help cancer cells survive and multiply.
The research team, co-led by Dr Mark Williams from the Research Centre for Health (ReaCH) at Glasgow Caledonian University, say the treatment could offer fresh hope for people with multiple myeloma.
Multiple myeloma affects plasma cells in the bone marrow and is currently considered incurable.
Treatment becomes even more challenging once the cancer becomes resistant to existing therapies.
Newsquest Scotland editor-in-chief to receive honorary doctorate in Glasgow
University lecturers set to walk out in Glasgow for 7 days
Warning as staff shortages causing ‘dangerous’ delays to cancer care
Dr Mark Williams, co-leader of the research from Glasgow Caledonian University’s Research Centre for Health, said: "This study highlights the exciting potential of PROTAC-based therapies to selectively eliminate proteins that drive cancer growth.
"CBPD-409 showed strong anti-myeloma activity in preclinical models, and these findings provide an important foundation for further research.
"While more work is needed before this approach can be tested in patients, the results point towards a promising new strategy for developing more precise and effective treatments for multiple myeloma."
Glasgow artist and giant 50kg Scottie dog conquer Ben Lomond for Maggie's
'We say no' Staff at UK's top modern university walk out as 100 jobs face the axe
Cancer charity reveals key role Glasgow played in helping people across UK
CBPD-409 uses PROTAC technology, which harnesses the body’s natural protein disposal system.
This approach goes further than conventional drugs, which only block protein activity.
In animal studies, CBPD-409 showed a significant reduction in tumour growth.
Dr Williams said: "PROTACs will likely become the next generation of highly effective treatments for cancers and non-cancerous conditions and, rather excitingly, in May of this year, the first PROTAC was clinically/FDA approved for the treatment of an aggressive type of breast cancer known as advanced or metastatic ESR1-mutated ER-positive/HER2-negative breast cancer."
This early breakthrough has emerged from an international study published in the Nature Portfolio journal Leukemia.
Share